Clinical Trial Update: Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bilateral intravitreal GS010 for Leber hereditary optic neuropathy due to the ND4 mutation has completed and posted efficacy and safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• GS010 (lenadogene nolparvovec)

Snippet

Sponsor: GenSight Biologics | Conditions: Leber Hereditary Optic Neuropathy | Phase 3 | Status: COMPLETED | Results posted: 2026-04-16